Integrative molecular navigator in preventable diseases: Pulmonary arterial hypertension (PAH) and rare diseases
Department of Public Health, School of Health Sciences and Practice, New York Medical College, Valhalla NY.
Review Article
GSC Biological and Pharmaceutical Sciences, 2020, 12(03), 204-207.
Article DOI: 10.30574/gscbps.2020.12.3.0285
Publication history:
Received on 31 August 2020; revised on 27 September 2020; accepted on 28 September 2020
Abstract:
Pulmonary arterial hypertension (PAH) is a debilitating lung condition for which there has been no cure that leads to complications on the right side of the heart. This disorder is currently distinguished from other conditions of the right ventricle by a DNA biorepository, invasive hemodynamics, echocardiography, genotype-tissue expression, imaging, and other diagnostic tools. Present treatment strategies include mainly medications and oxygen therapy choices. Advanced omics developments, including next generational genetic analysis, massively parallel gene-editing, metabolomics, and pharmacogenomics have significantly improved the volume of information that can be analyzed effectively in individuals with pulmonary arterial high blood pressure among other chronic illnesses. Emerging molecular-driven and gene targeting-driven evidence shed light on a new era of innovation as advanced clinical technology for providing patients quality of care in case of systemic arterial morbidity recognition, early diagnosis, therapeutic validation, and safety, including precision treatments based on patients’ genomic data pool obtained through genetic imprinting or genetic mapping.
Keywords:
Pulmonary arterial hypertension (PAH) metabolomics; Polymorphism; Pharmacogenomics; Drug safety; Gene editing
Full text article in PDF:
Copyright information:
Copyright © 2020 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
